poisar

Stocks · News reference

Amgen shares are trading higher after the company announced the Phase 3 OASIZ 301 study evaluating dazodalibep in adults with Sjögren's disease and moderate-to-severe systemic disease activity met its primary endpoint.

Benzinga Newsdesk
More stocks newsConnected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

AMGN
Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Delveinsight

    Global Autoimmune Disease Therapeutics Market is Predicted to Cross USD 60 Billion by 2034 | DelveInsight

    The global autoimmune disease therapeutics market is projected to grow from USD 133 billion in 2025 to USD 255 billion by 2034, with an 8% CAGR. Growth is driven by rising prevalence of autoimmune disorders, increasing adoption of biologics and targeted therapies, advancements in precision medicine, and expanding biosimilar availability. North America leads with 44% market share, while Asia-Pacific is the fastest-growing region. Key players include AbbVie, Johnson & Johnson, Pfizer, Novartis, and Roche.

    ABBVJNJPFENVSRHHBY
  2. Robert Izquierdo

    Better Healthcare ETF: Invesco's Biotech-Focused IBBQ vs. iShares' Broad IYH

    The Invesco Nasdaq Biotechnology ETF (IBBQ) offers lower costs (0.19% expense ratio) and higher 1-year returns (44.6%), making it suitable for growth-focused investors willing to accept volatility. The iShares U.S. Healthcare ETF (IYH) provides broader diversification across 100 healthcare holdings with higher dividend yield (1.1%) and lower volatility, appealing to conservative investors seeking stability and income.

    IBBQIYHLLYJNJABBV
  4. David Jagielski, Cpa

    The Schwab U.S. Dividend Equity ETF Is Near Its All-Time High: Is It Still a Good Buy?

    The Schwab U.S. Dividend Equity ETF (SCHD) has surged 22% this year and hit an all-time high, prompting questions about valuation. Despite the gains, the ETF maintains a reasonable price-to-earnings multiple of less than 20 (below the S&P 500's 23) and offers a 3% dividend yield, making it still attractive for income-focused investors seeking safety and quality dividend stocks.

    SCHDMRKABTAMGN